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What this paper adds 
What is already known on this subject? 
- Alpha1-antitrypsin (AAT) deficiency is among the most common genetic diseases. Homozygous 
carriers of the ‘PiZ’ variant of AAT are highly susceptible to develop liver cirrhosis due to ‘gain-of-
function’ toxicity of the mutant protein in hepatocytes. 
- Up to 10% of Caucasians carry an AAT variant but the relevance of heterozygous carriage for 
developing cirrhosis remains unclear. 
 
What this study adds 
- Heterozygous PiZ carriers (PiMZ) have markedly higher odds for developing liver fibrosis, 
especially in the setting of alcohol misuse or metabolic liver injury.  
- This finding warrants appropriate testing for the PiZ variant as a part of liver workup and a more 














Objectives: Homozygous carriers of the alpha1-antitrypsin (AAT) ‘PiZ’ variant are at risk for developing 
liver cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we evaluated (i) 
the prevalence of liver disease in heterozygous carriers of the PiZ variant (‘PiMZ’); and (ii) the impact of 
AAT variants on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse. 
Design: Case-control study. 
Setting: Multinational. 
Participants: (i) 176 PiMZ carriers (German-Austrian-Belgian-Dutch) and 176 non-carriers without AAT 
mutations. (ii) 643 people with NAFLD (German-Austrian) and 2462 people misusing alcohol (German-
Swiss & British-Irish). 
Main outcome measures: Development of liver fibrosis. 
Results: (i) PiMZ carriers had significantly higher liver enzyme and transient elastography (TE) values 
than non-carriers. The PiMZ genotype and obesity acted as independent risk factors for increased TE 
values suggesting significant liver fibrosis. (ii) The PiMZ genotype was present in 13.2% of cirrhotic 
NAFLD patients but only in 2.5% of patients without fibrosis (p<.0001). Accordingly, carriage of the PiZ 
variant predisposed NAFLD subjects to cirrhosis (adjusted OR=6.7 [1.5 to 31.0]). Likewise, the PiMZ 
genotype was present in 6.2% of alcohol misusers with cirrhosis but only in 2.2% of alcohol misusers 
without significant liver injury (p<.0001). Correspondingly, alcohol misusers carrying the PiZ variant were 
prone to develop cirrhosis (adjusted OR=5.8 [2.9 to 11.7]). These odds remained significant after 
adjustment for the established genetic variants. In contrast, the PiS variant showed no association with 
NAFLD-related cirrhosis and only a weak association with alcohol-related cirrhosis (adjusted OR=1.5 [1.0 
to 2.2]). 
Conclusions: The PiZ variant is the hitherto strongest single nucleotide polymorphism-based risk factor 
for liver fibrosis. This finding needs to be incorporated into genetic counseling of affected individuals. As 2-
4% of Caucasians are PiMZ carriers these data advocate for AAT testing as a part of liver workup. 
Trial registration: NCT02929940 
Keywords: Alpha1-antitrypsin deficiency, SERPINA1, SNP, alcoholic liver disease, non-alcoholic fatty 




Cirrhosis is the end-stage of all chronic liver diseases and is the result of a scarring process that is 
termed liver fibrosis. Together with its detrimental sequelae, cirrhosis constitutes a major and growing 
cause for morbidity and mortality worldwide(1). Therefore, a better understanding of the underlying genetic 
risk factors is highly relevant. Alcohol-related and non-alcohol-related liver diseases (ALD/NAFLD) are 
major causes of cirrhosis and liver-related mortality(2, 3). Both diseases share the same genetic risk 
factors. These comprise variants in the genes of patatin-like phospholipase domain-containing protein 3 
(PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), and membrane bound O-acyltransferase 
domain containing 7 (MBOAT7)(4, 5). These genetic variants have been identified by genome-wide 
association studies that are well suited for analysis of common genetic variants. However, variants that 
cause monogenic disorders are often rare and the genome-wide association approach fails to uncover 
such less frequent variants. A potential way to circumvent this problem is to directly address the biological 
role of genetic variants with a proven pathogenic potential. At this point, mutations in alpha1-antitrypsin 
(AAT; SERPINA1 gene) are attractive candidates. AAT is one of the most abundant serum proteins and is 
produced predominantly within hepatocytes(6). The presence of SERPINA1 variants typically lead to 
decreased serum AAT concentrations giving rise to the systemic disease alpha1-antitrypsin deficiency 
(AATD). Severe AATD is characterized by very low AAT serum levels (10-20% of normal), and constitutes 
a ’frequent rare disease’ with an incidence between 1:2000 and 1:4000(6-8). Accordingly, severe AATD is 
the third most common genetic disorder leading to death worldwide(7, 9). The lung and the liver are the 
organs most commonly affected and their involvement accounts for the high morbidity and mortality(7, 9). 
The nomenclature of AAT variants is based on the mobility of the resulting protein in the electric 
field(6, 9). The most relevant variant is termed ‘PiZ’ (rs28929474) which has a prevalence of up to 8% in 
Northern Europe(6, 8). The somewhat less severe variant, termed ‘PiS’ (rs17580), is more common in 
Southern Europe, with a prevalence of up to 20%(6). In total, approximately 120 million people worldwide 
carry at least one PiZ or PiS allele(6, 8). ‘PiMM’ describes the wild-type genotype and ‘PiZZ’ (i.e., the 
homozygous PiZ carriage) constitutes the classic severe AATD form(6, 7). While presence of the PiZZ 
genotype precipitates the development of liver disease(6, 10), the impact of heterozygous PiZ carriage 
(PiMZ genotype) is controversial(9). Even less well established is the impact of heterozygous or 
homozygous PiS carriage (PiMS or PiSS genotype, respectively) on liver disease.  
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Led by the a priori hypothesis that the presence of heterozygous AAT variants may spur the liver 
disease development in susceptible individuals, we evaluated the impact of heterozygous PiZ or PiS 
carriage in different settings. First, we studied a large cohort of heterozygous PiZ carriers. Secondly, we 
analysed well-described cohorts of patients with NAFLD and chronic alcohol misuse for the presence of 






















Cohort of PiMZ carriers and non-carriers 
A total of 352 adult carriers and non-carriers of the PiZ variant of self-reported European descent 
were recruited in the period from 1 April 2015 through 31 August 2017. None of the carriers and non-
carriers was known to have liver disease and the primary objective was to assess their extent of liver 
disease. 
Carriers (n=176) were defined as individuals with heterozygous carriage of the alpha1-antitrypsin 
(AAT) PiZ variant (‘PiMZ’ genotype). While some PiMZ carriers were known to have AATD, others have 
been recruited from families with a known case but had not themselves been genotyped previously. Only 
participants with a proven PiMZ genotype regardless of the AAT serum level were included. All carriers 
were recruited in close collaboration with the German, Belgian, Dutch, and Austrian patient advocacy 
groups as well as with respiratory physicians with a specialist interest in AATD. This awareness campaign 
was spear-headed by the University Hospital Aachen which is the coordinating center for AATD-related 
liver disease in two European initiatives (The European Association for the Study of the Liver (EASL) 
registry group ‘Alpha1-Liver’ and The European Reference Network (ERN) ‘Rare-Liver’) and was 
supported via an AATD liver-related homepage, telephone hotline, a presence on social media, as well as 
contributions to patient-centered periodicals. Individuals listed in the German national AATD registry were 
also offered a participation in the program.  
Non-carriers (n=176) had no evidence of any AAT mutation (‘PiMM’ genotype or wild-type). They 
had been recruited as spouses of patients with known AATD or as participants in a ‘liver awareness 
campaign’ organized by the University Hospital Aachen, Germany which provided a ‘liver check-up’ for the 
general population.  
The inclusion criteria were a valid assessment via transient elastography (TE; FibroScan, 
Echosens, Paris, France) of the liver and an ability to provide written informed consent. Main exclusion 
criteria were age <18 years and pregnancy. Study inclusion was offered at various sites and all comers 
have been examined. All examinations (questionnaires, clinical examination, blood sampling, and TE) 
were performed within the same day. Every participant filled out detailed, standardized questionnaires 
including information on demographic parameters, relevant comorbidities, alcohol consumption, etc. In all 
participants, the presence of a previously diagnosed liver disease has been excluded by personal 
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interview (e.g., no established diagnosis of chronic liver disease and no history of liver resection or liver 
transplantation) and clinical examination. Moreover, in both carriers and non-carriers, a comprehensive 
laboratory workup was performed using routine assays approved for use in clinical routine. Chronic 
infection with hepatitis B and C was excluded serologically in all subjects. Serum levels of ferritin and 
transferrin saturation were determined to assess for the presence of hereditary hemochromatosis and 
individuals with an otherwise unexplained elevation of ferritin and transferrin saturation were excluded (1 
PiMZ carrier, 1 PiMM non-carrier). Patients with self-reported excess alcohol consumption (>40g/d 
women, >60g/d men) were excluded (1 PiMZ carrier, 1 PiMM non-carrier). Finally, patients with elevated 
serum alanine transaminase (ALT) or aspartate transaminase (AST) activity >5x of the sex-specific upper 
limit of normal (ULN) or serum alkaline phosphatase (ALP) >2x of sex-specific ULN at time of recruitment 
were excluded (1 PiMZ carrier and no PiMM non-carrier) since marked elevation of these values preclude 
a reliable measurement of liver stiffness by TE. TE is the best established method for non-invasive 
assessment of liver fibrosis(11, 12) and was performed according to published recommendations (e.g., 
exclusion of confounders such as non-fasting or the presence of hepatic inflammation)(12). Previously 
suggested cut-offs for liver stiffness measurements were used(12). All measurements had been carried 
out by experienced physicians and only subjects with at least ten successful measurements and an 
interquartile range ≤30% of median liver stiffness were evaluated. All participants provided a written 
informed consent and were treated according to Ethical guidelines of the 1975 Declaration of Helsinki. The 
study was approved by the Internal Review Board of the participating centers and was registered on 
ClinicalTrials.gov (NCT02929940). 
Cohort of NAFLD subjects 
A total of 643 cases and controls of self-reported European descent were recruited from multiple 
sites in Germany and Austria. In all subjects, presence of non-alcoholic fatty liver disease (NAFLD) was 
diagnosed using liver biopsy. The presence of fibrosis was assessed according to Kleiner classification 
(stage F0: no fibrosis; stage F1: perisinusoidal fibrosis to portal/periportal fibrosis; stage F2: perisinusoidal 
and portal/periportal fibrosis; stage F3: bridging fibrosis; and stage F4: cirrhosis). Exclusion criteria were 
laboratory or clinical evidence of autoimmune, viral (serology for hepatitis B and C as well as HIV), or 
hereditary causes (serum ceruloplasmin and ferritin indicating the presence of Wilson disease and 
hereditary hemochromatosis, respectively) of liver disease, and clinically relevant alcohol consumption 
(self-reported consumption of >30 g/d for men and >20 g/d for women). Moreover, subjects with a current 
or previous use of steatosis-inducing drugs (e.g., amiodarone, methotrexate) were also excluded. 
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Cases (n=68) were defined as patients with biopsy-proven NAFLD-related cirrhosis (stage F4). 
Controls (n=362) had histological NAFLD without evidence of liver fibrosis (stage F0). In all NAFLD 
subjects, the relationship between fibrosis stage and the observed PiZ and PiS risk genotypes was 
analysed separately. 
A total of 359 German subjects were recruited during routine NAFLD workup at Leipzig, Frankfurt, 
Homburg, Kiel, and Hamburg and 284 Austrian subjects were recruited from ~2,500 participants in the 
’Salzburg Colon Cancer Prevention Initiative’ study and were examined in Oberndorf and Salzburg. Liver 
samples were obtained percutaneously in patients undergoing liver biopsy for suspected NAFLD/NASH or 
intraoperatively in patients in whom an intraoperative liver biopsy was indicated on clinical grounds such 
as during scheduled liver resection, exclusion of liver malignancy during major oncologic surgery, or 
assessment of liver histology during bariatric surgery. Portions of this NAFLD cohort have been described 
previously(13-19). All patients gave their written informed consent for liver biopsy and genetic testing. The 
study protocol was approved by the responsible local ethics committee of participating centers, and all 
subjects consented to inclusion in the study. 
Cohort of alcohol misusers 
A total of 2462 cases and controls were recruited from multiple centers. Of these, 1798 subjects 
were of self-reported German/Swiss descent (cases=934, controls=864) whereas 664 subjects were of 
self-reported British/Irish descent (cases=317, controls=347).  
Cases were defined as patients with alcohol-related cirrhosis (defined histologically or based on 
clinical, laboratory, endoscopic and imaging criteria) on a background of past and/or present alcohol 
consumption of at least 60 g/d for women and 80 g/d for men for more than 10 years, after exclusion of 
other common causes of cirrhosis. Controls had similar alcohol exposure but no evidence of advanced 
liver disease (based on clinical, laboratory, endoscopic and imaging criteria, non-invasive assessment of 
liver fibrosis or liver histology).  
German-Swiss cohort: A total of 1798 alcohol misusers of self-reported German or Swiss descent 
were examined. Cases with alcohol-related cirrhosis were recruited from the gastroenterology and 
hepatology departments of the university hospitals in Dresden, Leipzig, Bonn, Regensburg, Erlangen, 
Luebeck, Homburg, and Hamburg (all in Germany) or in Bern and Lausanne (Switzerland). Controls 
without evident liver disease were recruited at psychiatry centers specialized in addiction medicine in 
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Regensburg, Munich, and Mannheim (all in Germany). Past and present alcohol consumption was 
quantified through a face-to-face interview. All patients underwent clinical examination, standard 
laboratory testing, and abdominal ultrasound. Chronic infection with hepatitis B and C was excluded 
serologically in all subjects. Serum levels of ferritin and transferrin saturation were determined to rule out 
hereditary hemochromatosis, and neither clinical nor serological signs of autoimmune liver disease were 
present. Cases with alcohol-related cirrhosis were diagnosed on the basis of a history of alcohol 
dependence and histological examination of liver tissue; or compatible historical, clinical, laboratory, 
radiological, and endoscopic features. Controls were diagnosed on the basis of a history of alcohol 
dependence and the absence of significant liver injury on histology or else the absence of historical, 
clinical, radiological, or endoscopic features suggestive of significant liver injury either at presentation or 
during prolonged follow-up. Details of recruitment protocols were reported previously (20). All patients 
gave written informed consent, and the study received approval from the ethics committees of all 
participating centers.  
British-Irish cohort: 664 alcohol misusers of self-reported British or Irish descent were recruited 
from the Department of Hepatology at the Royal Free Hospital, London. All had a history of prolonged 
alcohol misuse and fulfilled DSM-IV criteria for a diagnosis of alcohol dependence. All were examined by 
two experienced, senior clinicians for signs of liver injury. Blood was taken at the time of presentation for 
standard liver function tests; serological testing was undertaken for antibodies to hepatitis A-E, 
cytomegalovirus, Epstein-Barr virus, herpes simplex and varicella; mitochondrial, nuclear, smooth muscle 
and liver kidney autoantibodies; iron, total iron binging capacity, ferritin; copper, caeruloplasmin; AAT and 
tissue transglutaminase. All patients underwent abdominal ultrasound and/or abdominal CT/MRI, as 
indicated; all underwent routine upper GI endoscopy; histological examination was undertaken, whenever 
possible, of liver biopsy material obtained by percutaneous, ultrasound guided or transjugular routes; or 
else of explant or post-mortem liver tissue. Patients were excluded if they had any other potential cause of 
liver injury or if they had a BMI >30 kg/m2 or were diabetic. Patients with AAT serum levels below 
laboratory reference range were genotyped (UK reference laboratory in Sheffield) and they were excluded 
if they had the PiZZ genotype. Cases with alcohol-related cirrhosis were diagnosed on the basis of a 
history of alcohol dependence and histological examination of liver tissue; or compatible historical, clinical, 
laboratory, radiological, and endoscopic features. Controls were diagnosed on the basis of a history of 
alcohol dependence and the absence of liver injury on histology or else the absence of historical, clinical, 
radiological, or endoscopic features suggestive of significant liver injury either at presentation or during 
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prolonged follow-up. Further details are stated elsewhere10. The study protocol was approved by the 
institutional review board, and all included subjects provided written informed consent.  
Genotyping 
All three cohorts were genotyped for the presence of the PiZ variant (rs28929474, also known as 
p.E342K or Glu342Lys) and the PiS variant (rs17580, also known as p.E264V or Glu288Val) of AAT. For 
the PiMZ carrier cohort, genomic DNA in participants without prior genotyping was genotyped by the 
German reference laboratory in Marburg as described before(21). For the NAFLD and alcohol misuser 
cohorts, genomic DNA from all cases and controls was genotyped using TaqMan chemistry (Applied 
Biosystems) as described before(20). Moreover, genotyping was performed for the PNPLA3 variant 
rs738409 (hcv7241), the TM6SF2 variant rs58542926 (hcv89463510), and the MBOAT7 variant rs641738 
(hcv8716820). All process data was logged and administered using a database-driven LIMS(22). 
Statistical analyses 
Continuous variables were displayed as mean±standard deviation (SD) and were compared by an 
unpaired, two-tailed t-test as well as by a multivariate linear model to account for relevant confounders. 
Categorical variables were reported as absolute (n) and relative (%) frequencies and contingency tables 
were analysed with Chi-square test. Mantel-Haenzsel linear-by-linear test for trend was used to assess 
the relationship between advanced fibrosis stage and observed PiZ and PiS risk genotypes in NAFLD 
subjects. Associations between clinical outcome parameters (e.g., liver stiffness, presence of cirrhosis) 
and potential risk factors (e.g., genotype) were assessed by binary logistic regression analysis in order to 
calculate odds ratios (OR). ORs were given with their corresponding 95% confidence intervals [in 
brackets]. Multivariable logistic regression was used to test for independent associations. Nominal two-
sided p values were reported for all tests and were corrected for multiple testing by Bonferroni correction, 
wherever appropriate. Fixed-effect model meta-analysis was performed using the inverse variance-
weighted method to summarise PiZ and PiS effect sizes in different cohorts. Herefore, the program META 
(1.6.0) was used.  
Differences were considered to be statistically significant when p<0.05. Statistical analyses were 
performed using SPSS version 23 (IBM, Armonk, NY, USA) and the graphs were created with Microsoft 




Patients were actively involved in the recruitment of the the PiMZ carrier/non-carrier cohort 
(details see above). In particular, we closely collaborated with various patient interest groups and offered 
examinations at various sites. As an appreciation of this joint effort, Pavel Strnad was elected as a 
member of the scientific advisory board of the German AATD patient advocacy group. Every study 
participant received a comprehensive evaluation as well as recommendations for further liver care. 













PiMZ carriers displayed an increased liver disease burden 
To assess the liver disease burden in individuals with the heterozygous ‘PiMZ’ genotype, we 
recruited a cohort of PiMZ carriers and non-carriers without known liver disease. Both groups displayed 
similar age, sex distribution, BMI values, and rates of diabetes mellitus (Table 1). Relevant alcohol 
consumption (>12g/d for women/>24g/d for men) was infrequent in both groups (individuals with 
consumption of >40g/d for women/>60g/d for men were excluded upfront), but tended to be more common 
in non-carriers (Table 1). As expected, PiMZ carriers had markedly lower serum AAT concentrations 
compared to non-carriers (Fig. 1A). The previously suggested cut-off AAT level of 110 mg/dL(23) 
discriminated well between both groups. Serum liver enzyme activities were increased above the sex-
adjusted upper limit of normal (ULN) in only a minority of PiMZ carriers: alanine aminotransferase (ALT): 
15.4%, aspartate aminotransferase (AST): 5.1%, and gamma-glutamyltransferase (GGT): 16.6%. The 
mean serum ALT, AST, and GGT activities were higher in PiMZ carriers than non-carriers (76% vs. 65% 
of ULN, 66% vs. 61% of ULN, and 78% vs. 55% of ULN, respectively; p<0.05 for all; Fig. 1B-D). In 
contrast, the cholestatic markers serum alkaline phosphatase (ALP) and serum bilirubin were not different 
between the groups (Fig. 1E-F). A multivariate adjustment of serum AAT, ALT, AST, GGT, ALP, and 
bilirubin for the covariates sex, age, BMI, and the presence of diabetes mellitus confirmed that the 
associations of serum AAT, ALT, AST and GGT concentrations with the genotype were independent 
(p<0.05 for all).  
Transient elastography (TE) revealed that 12.0% of PiMZ carriers vs. 4.5% of non-carriers 
displayed liver stiffness values ≥7.1 kPa, suggesting the presence of significant liver fibrosis (fibrosis stage 
of at least 2) (unadjusted OR=2.95 [95% CI 1.25 to 6.90], p=0.013). This association was more 
pronounced after adjusting for sex, age, BMI, and diabetes (OR=3.79 [1.47 to 9.77], p=0.006) and after 
further adjustment for mean alcohol consumption (OR=3.79 [1.47 to 9.79], p=0.006). In line, the average 
TE values were significantly higher in PiMZ carriers compared to non-carriers (5.0±1.7 vs. 4.4±1.4 kPa, 
univariate analysis: p=.0004, multivariate analysis accounting for age, sex, BMI, and diabetes: p=.0003; 
Fig. 2A). 
The mean (±1SD) TE values in non-obese patients (BMI <30 kg/m2) were normal irrespective of 
carrier status (PiMZ 4.7±1.4 vs. PiMM 4.3±1.3 kPa, p=0.047; Fig. 2B). The mean TE value in obese 
carriers was significantly higher than in non-carriers (PiMZ 6.4±1.9 vs PiMM 5.4±1.5 kPa, p=0.043; Fig. 
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2B).  Thus, TE values ≥7.1 kPa were uncommon in non-obese individuals regardless of their genotype 
(PiMM 3/143 [2.1%], PiMZ 9/137 [6.6%]), but were more common in obese subjects (PiMM 5/33 [15.2%], 
PiMZ 12/39 [30.8%]). Accordingly, obesity represented a risk factor for TE values ≥7.1 kPa in both 
genotypes (unadjusted odds: PiMM OR=8.87 [1.99 to 39.49], p=0.004; PiMZ OR=7.64 [2.80 to 20.85], 
p<0.0001). This association remained significant after adjustment for sex, age, diabetes, and alcohol 
consumption (PiMM: OR=7.07 [1.42 to 35.14], p=0.017; PiMZ: OR=9.75 [3.23 to 29.42], p<0.0001). 
Consecutive inclusion and testing of PiMZ genotype carriership, obesity (BMI ≥30 kg/m2) and their 
interaction term in a logistic regression model on the status of TE values ≥7.1 kPa, confirmed significant 
contributions by both PiMZ (p=0.02) and obesity (p<0.001). Their interaction (PiMZ x obesity) turned out to 
be non-significant (p=0.76) when subsequently added to this model. Consideration of BMI instead of 
dichotomized obesity status yielded very similar results, with an even stronger effect for PiMZ (OR=3.46 
[1.37 to 8.70], p=0.008). Hence, PiMZ and obesity act independently of each other as risk factors for the 
development of significant liver fibrosis. Collectively, these data indicate that the PiMZ genotype increases 
the risk of liver disease progression in the presence of a second hit. 
PiZ variant increased the risk to develop cirrhosis in NAFLD 
The increased liver stiffness in PiMZ carriers prompted us to investigate the role of AAT variants 
as disease modifier in patients with a second hit. First, we focused on patients with non-alcoholic fatty liver 
disease (NAFLD). Here, we genotyped a German-Austrian cohort of 643 patients with biopsy-proven 
NAFLD for the presence of the PiZ and the PiS variants (Supplementary table 1). No patient had the 
homozygous PiSS or PiZZ genotype or the compound heterozygous PiSZ genotype. A comparison of 
carriers of the PiMZ and PiMS genotype with non-carriers revealed that PiMZ carriers but not PiMS 
carriers displayed a significant shift towards higher fibrosis stages (p=0.001 and p=0.320, respectively; 
Supplementary table 1). 
Noteworthy, the PiMZ genotype was overrepresented in NAFLD patients with cirrhosis vs. no 
fibrosis (13.2% vs. 2.5%, p<0.0001; Supplementary table 2), while the PiMS genotype was detected at 
comparable frequencies (4.4% vs. 3.9%, p=0.740; Supplementary table 2).  
The PiZ variant constituted a strong risk factor for developing NAFLD-related cirrhosis (F4) vs. no 
fibrosis (F0) in the univariate analysis (unadjusted OR=5.76 [1.82 to 18.24], p=0.003; Fig. 3A). This 
association remained significant after multivariate adjustment for sex, age, BMI, and diabetes (OR=6.73 
[1.46 to 30.99], p=0.014; Fig. 3B).  
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In contrast to the PiZ variant, no link with cirrhosis development was found for the PiS variant, 
neither in the univariate analysis (OR=1.71 [0.37 to 8.05], p=0.495; Supplementary fig. 1A), nor after 
adjusting for sex, age, BMI, and diabetes (adjusted OR=1.77 [0.32 to 9.83], p=0.516; Supplementary fig. 
1B).  
Taken together, the presence of the PiZ variant, but not the PiS variant, constitutes a strong risk 
factor to develop NAFLD-related cirrhosis.  
PiZ variant increased the risk to develop cirrhosis in alcohol misusers 
The link between the PiZ variant and the development of liver disease in NAFLD patients 
prompted us to investigate the impact of the same two AAT variants, PiZ and PiS, in two well-
characterized cohorts of alcohol misusers, which in total comprised 2462 individuals (German-Swiss 
cohort, Supplementary table 3, and British-Irish cohort, Supplementary table 4). Similar to the NAFLD 
cohort, the PiMZ genotype was overrepresented amongst patients with alcohol-related cirrhosis compared 
to controls (German-Swiss: 6.2% vs. 2.0%, p<0.0001, Supplementary table 3; British-Irish: 6.0% vs. 2.6%, 
p=0.029, Supplementary table 4; both cohorts: 6.2% vs. 2.2%, p<0.0001). The PiMS genotype was also 
overrepresented amongst patients with alcohol-related cirrhosis in the German-Swiss cohort compared to 
controls (7.9% vs. 5.5%, p=0.046; Supplementary table 3) but not in the British-Irish cohort (10.5% vs. 
8.2%; p=0.295; Supplementary table 4). Notably, we also identified four subjects with previously unknown 
homozygous PiZ carriage (PiZZ genotype) in the German-Swiss cohort as measurement of the AAT 
serum level was not part of the initial assessment. Moreover, eight patients were newly discovered as 
compound heterozygotes (PiSZ genotype). Eleven out of the twelve PiZZ and PiSZ patients had already 
developed cirrhosis (Supplementary tables 3 and 4). Five patients were homozygous for the PiS variant 
(PiSS genotype); three of them had cirrhosis (Supplementary tables 3 and 4).  
In line with these data, the presence of the PiZ variant was strongly associated with the risk of 
developing cirrhosis in alcohol misusers in the univariate analysis (German-Swiss: OR=5.35 [2.53 to 
11.34], p<0.0001; British-Irish: OR=4.88 [1.42 to 16.76], p=0.012; meta-analysis: OR=5.22 [2.75 to 9.91], 
p<0.0001; Fig. 4A). This association was more pronounced when the data were adjusted for sex, age, 
BMI, and diabetes (German-Swiss: OR=6.14 [2.63 to 14.31], p=<0.0001; British-Irish: OR=5.11 [1.47 to 
17.81], p=0.010; meta-analysis: OR=5.79 [2.87 to 11.68], p=<0.0001; Fig. 4B). Moreover, this association 
remained significant after further adjusting for risk variants in PNPLA3, TM6SF2, and MBOAT7, which are 
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well-established ALD modifiers (German-Swiss: OR=6.05 [2.54 to 14.43], p<0.0001; British-Irish: OR=5.24 
[1.45 to 18.85], p=0.011; meta-analysis: OR=5.78 [2.82 to 11.87], p<0.0001).  
In contrast to the PiZ variant, no or only a weak association was observed between the PiS 
variant and the risk of developing cirrhosis in the univariate analysis (German-Swiss: OR=1.79 [1.15 to 
2.79], p=0.010; British-Irish: OR=1.10 [0.60 to 2.01], p=0.750; meta-analysis: OR=1.51 [1.06 to 2.15], 
p=0.024; Supplementary fig. 2A). After multivariate adjustment for sex, age, BMI, and diabetes, this 
association remained significant in the German-Swiss cohort but lost its significance in the meta-analysis 
(German-Swiss: OR=1.70 [1.01 to 2.87], p=0.047; British-Irish: OR=1.20 [0.65 to 2.22], p=0.557; meta-
analysis: OR=1.47 [0.99 to 2.19], p=0.058; Supplementary fig. 2B). Moreover, after further adjustment for 
the variants in the PNPLA3, TM6SF2, and MBOAT7 genes this association was lost (German-Swiss: 
OR=1.56 [0.89 to 2.74], p=0.123; British-Irish: OR=1.21 [0.62 to 2.36], p=0.570; meta-analysis: OR=1.40 
[0.91 to 2.16], p=0.122).  
Altogether, our data indicate that carriage of the PiZ variant represents a strong factor 




In the present study, for the first time, we prospectively evaluated liver injury and the stage of liver 
fibrosis in PiMZ carriers. The fact that PiMZ subjects display higher liver enzyme levels and higher liver 
stiffness than those without AAT mutations does suggest that PiMZ carriers either have subclinical liver 
disease and/or are more susceptible to develop liver disease after a second hit. In addition to our genetic 
association data, the increased TE values found in obese PiMZs support the second-hit theory. With 
regard to that, the detrimental role of obesity for liver injury in general is well established(24). Obesity was 
also shown to predispose patients with severe AATD (homozygous PiZZ genotype) to advanced liver 
disease(25).  
To further substantiate the data from the PiMZ cohort, we took advantage of a well-defined cohort 
of patients with biopsy-proven NAFLD (n=643) and two large, well-characterized cohorts of alcohol 
misusers (n=2462). We unambiguously found that the PiZ variant is a major risk factor for ALD- and 
NAFLD-related cirrhosis. These findings are in line with previously published, smaller studies(26-29). 
Moreover, this study is the first report that has systematically investigated the role of the PiS variant 
providing evidence that this variant may also pose a weak risk to develop alcoholic cirrhosis, but further 
studies are needed to confirm this association. These observations mesh well with the known pathogenic 
significance of both PiS and PiZ variants. Because PiS forms fewer polymers than PiZ, it is less retained 
within hepatocytes leading to a less prominent endoplasmic reticulum (ER) protein overload than PiZ(30).  
Our findings demonstrate that the PiZ variant confers an approximately six times higher odd to 
develop both NAFLD- and ALD-associated cirrhosis. With a frequency of 2-4% in Europe the PiZ variant is 
relatively rare(6, 8, 9), but shows remarkable odds posing this variant as the hitherto strongest known 
genetic risk factor for NAFLD- and ALD-related cirrhosis. In fact, the odds ratio for developing cirrhosis of 
the PiZ variant exceed the odds ratios of other, well-established genetic risk factors, such as the PNPLA3 
variant rs738409, the MBOAT7 variant rs641738, and the TM6SF2 variants rs10401969/rs58542926(20, 
31-33).  
While future research needs to define the exact molecular mechanism how AAT variants 
predispose for NAFLD- and ALD-related liver fibrosis and what clinical modifiers are of particular 
importance, several factors are likely relevant. The cellular retention of mutated AAT (such as the PiZ 
variant) leads to a gain-of-function toxicity that is proportional to the amount of retained protein(9). 
Notably, AAT constitutes an established acute phase protein that is induced in patients suffering from liver 
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injury(34). Among other factors, ethanol was shown to stimulate AAT production in a human hepatoma 
cell line(35), and thus, might aggravate gain-of-function toxicity in patients with AATD. Additionally, AAT 
mutations lower the threshold for an ER stress response(36); which might be particularly relevant in 
NAFLD and ALD as both also challenge the ER(9, 37). Moreover, autophagy is crucial for the degradation 
of mutated AAT(36) and both NAFLD and ALD have been shown to impair autophagic activity in 
hepatocytes(38, 39). Finally, an increased activity of neutrophil elastase, that constitutes the most 
established AAT substrate, has been implicated in the development of obesity and insulin resistance(40). 
This pathway might be particularly important in subjects with AAT variants that display decreased serum 
AAT levels(9). 
The fact that the PiZ variant constitutes a clear and strong disease modifier should prompt its 
assessment in the workup of liver disease. In that respect, measuring serum AAT levels represents a 
relatively easy and cost-efficient method to rule out severe AATD (i.e., homozygous PiZZ genotype)(23) 
However, detecting heterozygous individuals (e.g., PiMZ genotype) is more challenging as their AAT 
serum level are often within the reference range. Further research is needed to define an optimal serum 
AAT cut-off level, especially in the context of chronic liver disease. In summary, our study defines the PiZ 
variant as an obvious single nucleotide polymorphism-based risk factor to develop NAFLD- and ALD-
associated cirrhosis. At the same time, our data advocate for a careful assessment of AAT serum levels in 
patients with chronic liver disease. They also encourage a more thorough clinical monitoring and 
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Table 1: Features of individuals with heterozygous carriage of the alpha1-antitrypsin PiZ variant 










Demographics    
Age (years) 47.0.0±13.4 47.0±15.5 0.956 
Women  104 (59.1) 104 (59.1) 1.000 
    
Risk factors    
BMI (kg/m2) 25.7±4.7 25.7±4.5 0.994 
Diabetes mellitus (yes/no/NA, % yes) 6/160/10 (3.6) 7/147/22 (4.5) 0.673 
Relevant alcohol intake+ (yes/no/NA, % yes) 20/154/2 (11.5) 10/155/11 (6.1) 0.078 
 
Quantitative measures are expressed as mean with standard deviation or as absolute count (n) with 
relative frequency (%). Abbreviations: BMI, body mass index; NA, not available. +Alcohol intake >12g/d 
women, >24g/d men. 
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Fibrosis stage F0 362 9 (2.5) 14 (3.9) 
Fibrosis stage F1 144 12 (8.3) 6 (4.2) 
Fibrosis stage F2 35 5 (14.3) 2 (5.7) 
Fibrosis stage F3 34 1 (2.9) 4 (11.8) 
Fibrosis stage F4 68 9 (13.2) 3 (4.4) 
 
The absolute count (n) and relative frequency (%) of the analysed individuals are displayed. Only 
individuals carrying the PiMZ or PiMS genotype are displayed as there were no individuals with the PiZZ, 
PiSS, or PiSZ genotype. Abbreviations: PiMZ=heterozygous for the PiZ variant; PiMS=heterozygous for 
the PiS variant; PiZZ=homozygous for the PiZ variant; PiSS=homozygous for the PiS variant; 



















Characteristics     
Age (years) 49±14 46±13 61±13 <0.0001 
Women  322 (50) 165 (46) 41 (60) 0.026 
BMI (kg/m2) 37±12 36±12 28±7 <0.0001 
Diabetes mellitus 
(yes/no/NA, % yes) 
188/403/52 (32) 84/265/13 (24) 24/14/30 (63) <0.0001 
     
Frequency of AAT 
genotypes 
    
PiMZ genotype 34 (5.3) 9 (2.5) 9 (13.2) <0.0001 
PiZZ genotype 0 (0) 0 (0) 0 (0) NA 
PiMS genotype 29 (4.5) 14 (3.9) 3 (4.4) 0.740* 
PiSS genotype  0 (0) 0 (0) 0 (0) NA 
PiSZ genotype  0 (0) 0 (0) 0 (0) NA 
 
Cases were defined as NAFLD patients with histological cirrhosis (stage F4) whereas controls were 
defined as NAFLD patients without histological evidence of fibrosis (stage F0). Quantitative measures are 
shown as mean ± standard deviation or as an absolute count (n) and relative frequency (%). 
Abbreviations: BMI, body mass index; NA, not available/applicable; PiMZ=heterozygous for the PiZ 
variant; PiZZ=homozygous for the PiZ variant; PiMS=heterozygous for the PiS variant; PiSS=homozygous 




















Characteristics     
Age (years) 51±11 45±10 56±10 <0.0001 
Women  386 (22) 118 (14) 268 (29) <0.0001 
BMI (kg/m2) 25.6±4.6 24.9±4.9 26.3±5.0 <0.0001 
Diabetes mellitus 
(yes/no/NA, % yes) 
209/1199/390 (15) 13/612/239 (2) 196/587/151 (25) <0.0001 
     
Frequency of AAT 
genotypes 
    
PiMZ genotype  75 (4.17) 17 (1.97) 58 (6.21) <0.0001 
PiZZ genotype  4 (0.12) 0 (0) 4 (0.43) 0.073* 
PiMS genotype+ 120 (6.77) 47 (5.53) 73 (7.92) 0.046 
PiSS genotype+ 3 (0.17) 1 (0.06) 2 (0.11) 0.390* 
PiSZ genotype+ 6 (0.34) 0 (0) 6 (0.65) 0.019* 
 
Cases were defined as alcohol misusers with cirrhosis whereas controls were defined as alcohol misusers 
without evidence of significant liver injury. Quantitative measures are shown as mean ± standard deviation 
or as an absolute count (n) and relative frequency (%). Abbreviations: BMI, body mass index; NA, not 
available; PiMZ=heterozygous for the PiZ variant; PiZZ=homozygous for the PiZ variant; 
PiMS=heterozygous for the PiS variant; PiSS=homozygous for the PiS variant; PiSZ=compound 
heterozygous for the PiS and the PiZ variant. +1772 subjects (98.6% of all subjects) were genotyped for 









Supplementary Table 4: Characteristics of British-Irish cohort of alcohol misusers. 
 
 
Cases were defined as alcohol misusers with cirrhosis whereas controls were defined as alcohol misusers 
without evidence of significant liver injury. Quantitative measures are shown as mean ± standard deviation 
or as an absolute count (n) and relative frequency (%). Abbreviations: BMI, body mass index; 
PiMZ=heterozygous for the PiZ variant; PiZZ=homozygous for the PiZ variant; PiMS=heterozygous for the 
PiS variant; PiSS=homozygous for the PiS variant; PiSZ=compound heterozygous for the PiS and the PiZ 
variant; NA, not applicable. °Diabetic subjects and/or subjects with BMI >30 kg/m2 have been excluded a 
priori. #Patients with the PiZZ genotype were excluded a priori. +656 subjects (98.8% of all subjects) were 


























Characteristics     
Age (years) 51±11 49±10 53±10 <0.0001 
Women  180 (27) 81 (23) 99 (31) 0.022 
BMI (kg/m2)° 24.7±2.5 24.7±2.3 24.6±2.6 0.901 
Diabetes mellitus 
(yes/no/NA, % yes)° 
- - - - 
     
Frequency of AAT 
genotypes 
    
PiMZ genotype  28 (4.22) 9 (2.59) 19 (5.99) 0.029 
PiZZ genotype# 0 (0) 0 (0) 0 (0) NA 
PiMS genotype+  61 (9.30) 28 (8.16) 33 (10.54) 0.295  
PiSS genotype+ 2 (0.30) 1 (0.29) 1 (0.32) 0.499* 
PiSZ genotype+  2 (0.30) 1 (0.29) 1 (0.32) 0.499* 
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Figures and Figure Legends 
 
Figure 1: Serum alpha1-antitrypsin (AAT) and liver enzyme concentrations in carriers 
heterozygous for the alpha1-antitrypsin PiZ variant (MZ) and non-carriers (MM). 
176 carriers and 176 non-carriers undertook laboratory analysis. A) Scatter plot of the absolute serum 
AAT concentrations: The lower dotted line represents the commonly used lower limit of normal (90 
mg/dL). The upper dotted line represents the 110 mg/dL cut-off level which was previously suggested to 
better discriminate between individuals with the PiMZ and PiMM genotype. B-F) Scatter plots depict liver 
enzyme activities as well as cholestatic markers normalized to the sex-specific upper limit of normal (ULN) 
which is marked as a dotted line. Abbreviations: MM, wild-type genotype (PiMM); MZ, heterozygous 
carriage of the PiZ variant (PiMZ); ALT, alanine aminotransferase, AST, aspartate aminotransferase; 













Figure 2: Liver stiffness evaluated by transient elastography in carriers heterozygous for the 
alpha1-antitrypsin PiZ variant (MZ) and non-carriers (MM). 
176 carriers and 176 non-carriers without a previously known liver disease have been prospectively 
evaluated by transient elastography (FibroScan, Echosens). The horizontal dotted lines indicate the 
established liver stiffness cut-off levels associated with increasing degrees of hepatic fibrosis, namely: 
fibrosis stage ≥2 - 7.1 kPa, fibrosis stage ≥3 – 10 kPa, fibrosis stage 4 – 13 kPa. Abbreviations: MM, wild-








Figure 3: Risk of developing cirrhosis in biopsy-proven NAFLD patients heterozygous for the 
alpha1-antitrypsin PiZ variant. 
An univariate (A) and a multivariate (B) analysis in 378 patients with non-alcoholic fatty liver disease 
(NAFLD) from Germany and Austria, the latter was adjusted for sex, age, body mass index, and the 
presence of diabetes mellitus. The odds for developing cirrhosis (stage F4) vs. no fibrosis (stage F0) are 








Figure 4: Analysis of the risk of developing cirrhosis in two cohorts of alcohol misusers 
heterozygous for the alpha1-antitrypsin PiZ variant.An univariate (A) and a multivariate (B) analysis 
was performed in 1191 alcohol misusers from Germany and Switzerland as well as 440 alcohol misusers 
from Great Britain and Ireland, both cohorts with and without cirrhosis. Adjustments were made for sex, 
age, body mass index, and the presence of diabetes mellitus. The term “overall” depicts the meta-analysis 







Supplementary figure 1: Odds for cirrhosis development in biopsy-proven NAFLD individuals 
carrying the alpha1-antitrypsin PiS variant. 
An univariate (A) and a multivariate (B) analysis was performed in 378 patients with non-alcoholic fatty 
liver disease (NAFLD) from Germany and Austria, the latter was adjusted for sex, age, body mass index, 
and the presence of diabetes mellitus. The odds for developing liver cirrhosis (stage F4) vs. no fibrosis 









Supplementary figure 2: Analysis of the risk of developing cirrhosis in two cohorts of alcohol 
misusers carrying the alpha1-antitrypsin PiS variant. 
An univariate (A) and a multivariate (B) analysis was performed in 1176 alcohol misusers from Germany 
and Switzerland as well as 437 alcohol misusers from Great Britain and Ireland, both cohorts with and 
without cirrhosis. Adjustments were made for sex, age, body mass index, and the presence of diabetes 
mellitus. The term “overall” depicts the meta-analysis of both cohorts. Abbreviations: OR, odds ratio. 
 
